var data={"title":"Adenosine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Adenosine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5573?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=adenosine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Adenosine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Adenosine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130686\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adenocard;</li>\n      <li>Adenoscan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130687\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adenocard;</li>\n      <li>Adenosine Injection, USP;</li>\n      <li>PMS-Adenosine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130728\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Miscellaneous;</li>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130690\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal supraventricular tachycardia (Adenocard):</b> IV (rapid, over 1 to 2 seconds, via peripheral line; see <b>Note</b>): Initial: 6 mg; if not effective within 1 to 2 minutes, 12 mg may be given; may repeat 12 mg bolus if needed (maximum single dose: 12 mg). Follow each dose with 20 mL normal saline flush. <b>Note:</b> Initial dose of adenosine should be reduced to 3 mg if patient is currently receiving carbamazepine or dipyridamole, has a transplanted heart or if adenosine is administered via central line (ACLS 2010; Chang 2002). A subsequent bolus dose of 18 mg (following an initial dose of 6 mg and a repeat bolus dose of 12 mg) has reportedly been used in patients with sustained SVTs (ACC/AHA/HRS [Page 2015]; Domanovits 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharmacologic stress testing (Adenoscan):</b> IV: Continuous IV infusion via peripheral line: 140 mcg/kg/minute for 6 minutes using syringe or volumetric infusion pump; total dose: 840 mcg/kg. Thallium-201 is injected at midpoint (3 minutes) of infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute vasodilator testing in pulmonary artery hypertension (off-label use) (Adenoscan): </b> IV: Initial: 50 mcg/kg/minute increased by 50 mcg/kg/minute every 2 minutes to a maximum dose of 500 mcg/kg/minute (Schrader 1992) <b>or</b> to a maximum dose of 350 mcg/kg/minute (ACCF/AHA [McLaughlin, 2009]; ESC/ERS/ISHLT [Galie 2009]; Zuo 2012); acutely assess vasodilator response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fractional flow reserve testing (diagnostic aid) (off-</b>\n      <b>label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 140 mcg/kg/minute as a continuous infusion during testing (Schlundt 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intracoronary: 40 mcg into the right coronary artery or 80 mcg into the left coronary artery; dilute dose in 10 mL of NS and administer rapidly through the guiding catheter (R&ouml;ther 2016; Schlundt 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130709\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Adenosine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b> Rapid IV push (over 1 to 2 seconds) via peripheral line, followed by a normal saline flush: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal supraventricular tachycardia (Adenocard):</b> Infants and Children: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;50 kg: Initial: 0.05 to 0.1 mg/kg (maximum initial dose: 6 mg). If conversion of PSVT does not occur within 1 to 2 minutes, may increase dose by 0.05 to 0.1 mg/kg. May repeat until sinus rhythm is established or to a maximum single dose of 0.3 mg/kg or 12 mg. Follow each dose with normal saline flush.</p>\n    <p style=\"text-indent:2em;margin-left:2em;\">Children &ge;50 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediatric advanced life support (PALS, 2010):</i> Treatment of SVT: IV, Intraosseous: Initial: 0.1 mg/kg (maximum initial dose: 6 mg); if not effective within 1 to 2 minutes, administer 0.2 mg/kg (maximum single dose: 12 mg). Follow each dose with &ge;5 mL normal saline flush.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130691\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Elderly may be more sensitive to effects of adenosine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671324\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, adenosine is not renally eliminated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671325\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, adenosine is not hepatically eliminated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130666\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adenocard: 6 mg/2 mL (2 mL); 12 mg/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adenoscan: 3 mg/mL (20 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg/mL (20 mL, 30 mL); 6 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg/mL (20 mL, 30 mL); 6 mg/2 mL (2 mL); 12 mg/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 90 mg/30 mL (30 mL); 60 mg/20 mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130651\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130670\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenocard: For rapid bolus IV use only; administer IV push over 1 to 2 seconds at a peripheral IV site as proximal as possible to trunk (not in lower arm, hand, lower leg, or foot); follow each bolus with a rapid normal saline flush (infants and children &ge;5 mL; adults 20 mL). Use of 2 syringes (one with adenosine dose and the other with NS flush) connected to a T-connector or stopcock is recommended. If administered via <b>central line</b> in adults, reduce initial dose to 3 mg (ACLS 2010; Chang 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fractional flow reserve testing (off-label use): Intracoronary: Give rapidly followed by a 10 mL NS flush (R&ouml;ther 2016; Schlundt 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenoscan: For IV infusion only via peripheral line</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130669\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal supraventricular tachycardia:</b> Adenocard: Treatment of paroxysmal supraventricular tachycardia (PSVT) including that associated with accessory bypass tracts (Wolff-Parkinson-White syndrome); when clinically advisable, appropriate vagal maneuvers should be attempted prior to adenosine administration; <b>not effective for conversion of atrial fibrillation, atrial flutter, or ventricular tachycardia</b></p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> While adenosine will not convert atrial fibrillation or atrial flutter, the transient AV-nodal block may aid in the identification of the arrhythmia by exposing the underlying atrial fibrillation or flutter electrocardiographic morphology.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b> The American College of Cardiology/American Heart Association/Heart Rhythm Society supraventricular tachycardia (SVT) guidelines recommends adenosine in the acute management of a variety of SVTs (eg, AV nodal reentrant tachycardia [AVNRT], AV reentrant tachycardia [AVRT]) (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diagnostic aid: </b>Adenoscan: Pharmacologic stress agent used in myocardial perfusion thallium-201 scintigraphy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720645\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Fractional flow reserve testing (diagnostic aid); Monomorphic wide-complex tachycardia (stable); Narrow-complex regular tachycardia (stable); Narrow-complex regular tachycardia (unstable); Pulmonary artery hypertension (acute vasodilator testing)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174500\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130658\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequency varies based on use and is not always defined; higher frequency of infusion-related effects, such as flushing and lightheadedness/dizziness, were reported with continuous infusion (Adenoscan). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia (transient and new arrhythmia after cardioversion; eg, atrial premature contractions, atrial fibrillation, premature ventricular contractions; 55%), chest pressure (and discomfort; 7% to 40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 18%), dizziness (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Facial flushing (18% to 44%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal distress (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Neck discomfort (includes throat, jaw; &lt;1% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (12% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Atrioventricular block (infusion 6%; third-degree &lt;1%), depression of ST segment on ECG (3%), hypotension (&lt;1% to 2%), chest pain, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Nervousness (2%), paresthesia (&le;2%), numbness (1%), apprehension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Upper extremity discomfort (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Hyperventilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Asystole (prolonged), atrial fibrillation, blurred vision, bradycardia, bronchospasm, burning sensation, cardiac arrest (fatal and nonfatal), increased intracranial pressure, injection site reaction, loss of consciousness, metallic taste, myocardial infarction, respiratory arrest, seizure, torsades de pointes, transient hypertension, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130673\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to adenosine or any component of the formulation; second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia (except in patients with a functioning artificial pacemaker); known or suspected bronchoconstrictive or bronchospastic lung disease (Adenoscan), asthma (ACLS [Neumar, 2010]; Adenoscan prescribing information, 2014) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130655\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Atrial fibrillation/flutter: There have been reports of atrial fibrillation/flutter when administered to patients with paroxysmal supraventricular tachycardia (PSVT) and may be especially problematic in patients with PSVT and underlying Wolff-Parkinson-White syndrome; has also been reported in patients with or without a history of atrial fibrillation undergoing myocardial perfusion imaging with adenosine infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular events (Adenoscan): Cardiac arrest (fatal and nonfatal), myocardial infarction (MI), cerebrovascular accident (hemorrhagic and ischemic), and sustained ventricular tachycardia (requiring resuscitation) have occurred following Adenoscan use. Avoid use in patients with signs or symptoms of unstable angina, acute myocardial ischemia, or cardiovascular instability due to possible increased risk of significant cardiovascular consequences. Appropriate measures for resuscitation should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conduction disturbances: Adenosine decreases conduction through the AV node and may produce first-, second-, or third-degree heart block. Patients with preexisting SA nodal dysfunction may experience prolonged sinus pauses after adenosine; use caution in patients with first-degree AV block or bundle branch block; use is contraindicated in patients with high-grade AV block,  sinus node dysfunction, or symptomatic bradycardia (unless a functional artificial pacemaker is in place). Rare, prolonged episodes of asystole have been reported, with fatal outcomes in some cases. Discontinue adenosine in any patient who develops persistent or symptomatic high-grade AV block.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Hypersensitivity reactions (including dyspnea, pharyngeal edema, erythema, flushing, rash, or chest discomfort) have been reported following Adenoscan administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Hypertension: Systolic and diastolic pressure increases have been observed with Adenoscan infusion. In most instances, blood pressure increases resolved spontaneously within several minutes; occasionally, hypertension lasted for several hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension: May produce profound vasodilation with subsequent hypotension. When used as a bolus dose (PSVT), effects are generally self-limiting (due to the short half-life of adenosine). However, when used as a continuous infusion (pharmacologic stress testing), effects may be more pronounced and persistent, corresponding to continued exposure. Use infusions with caution in patients with autonomic dysfunction, carotid stenosis (with cerebrovascular insufficiency), hypovolemia, pericarditis, pleural effusion and/or stenotic valvular heart disease; discontinue infusion in patients who develop persistent or symptomatic hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Proarrhythmic effects: Monitor for proarrhythmic effects (eg, polymorphic ventricular tachycardia) during and shortly after administration/termination of arrhythmia. The benign transient occurrence of atrial and ventricular ectopy is common upon termination of arrhythmia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Seizures (new-onset or recurrent) have been reported following Adenoscan administration; risk may be increased with concurrent use of aminophylline. Use of any methylxanthine (eg aminophylline, caffeine, theophylline) is not recommended in patients experiencing seizures associated with Adenoscan administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmia (wide-complex tachycardia): Avoid use in irregular or polymorphic wide-complex tachycardias; may cause degeneration to ventricular fibrillation (ACLS, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart transplant recipients: Use with extreme caution in heart transplant recipients; adenosine may cause prolonged asystole; reduction of initial adenosine dose is recommended (ACLS, 2010); considered by some to be contraindicated in this setting (Delacr&eacute;taz, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary artery hypertension: Acute vasodilator testing (not an approved use): Use with extreme caution in patients with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; significant decompensation has occurred with other highly selective pulmonary vasodilators resulting in acute pulmonary edema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Avoid use in patients with bronchoconstriction or bronchospasm (eg, asthma); dyspnea, bronchoconstriction, and respiratory compromise have occurred during use. Per the ACLS guidelines and the manufacturer of Adenoscan, use considered contraindicated in patients with asthma. Use caution in patients with obstructive lung disease not associated with bronchoconstriction (eg, emphysema, bronchitis). Immediately discontinue therapy if severe respiratory difficulty is observed. Appropriate measures for resuscitation should be available during use. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Wolff-Parkinson-White (WPW) syndrome: Adenosine should not be used in patients with WPW syndrome and preexcited atrial fibrillation/flutter since ventricular fibrillation may result (AHA/ACC/HRS [January, 2014]). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Caffeine: Pharmacologic stress testing: Since caffeine antagonizes the activity of adenosine, withhold for 5 half-lives prior to adenosine use; avoid dietary caffeine for at least 12 hours prior to pharmacologic stress testing (Henzlova, 2006). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carbamazepine: Concomitant use potentiates the effects of adenosine; reduction of initial adenosine dose is recommended when used for SVT (ACLS, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dipyridamole: Concomitant use potentiates the effects of adenosine; reduction of initial adenosine dose is recommended when used for SVT (ACLS, 2010); withhold dipyridamole-containing medications for at least 24 hours prior to pharmacologic stress testing (Henzlova, 2006)  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drugs which slow AV node conduction: Use with caution in patients receiving other drugs which slow AV node conduction (eg, digoxin, verapamil).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Theophylline (includes aminophylline): Pharmacologic stress testing: Since theophylline antagonizes the activity of adenosine, withhold for 5 half-lives prior to adenosine use whenever possible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; may be at increased risk of hemodynamic effects, bradycardia, and/or AV block. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adenocard: Transient AV block is expected. When used in PSVT, at the time of conversion to normal sinus rhythm, a variety of new rhythms may appear on the ECG. Administer as a rapid bolus, either directly into a vein or (if administered into an IV line), as close to the patient as possible (followed by saline flush). Dose reduction recommended when administered via central line (ACLS, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: ECG monitoring is required during use. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available. Adenosine does not convert atrial fibrillation/flutter to normal sinus rhythm; however, may be used diagnostically in these settings if the underlying rhythm is not apparent. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298689\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130660\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9359&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and Caffeine Containing Products: May diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving caffeine. Discontinue caffeine in advance of scheduled diagnostic use of adenosine whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased. Management: Consider using a lower initial dose of adenosine in patients who are receiving carbamazepine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: May enhance the adverse/toxic effect of Adenosine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the adverse/toxic effect of Adenosine. Specifically, cardiovascular effects of adenosine may be enhanced.  Adenosine dose reduction may be needed. Management: Reduction of the initial dose of adenosine may be warranted.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicotine: May enhance the AV-blocking effect of Adenosine. Nicotine may enhance the tachycardic effect of Adenosine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May diminish the therapeutic effect of Adenosine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130662\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130675\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Adenosine is an endogenous substance and adverse fetal effects would not be anticipated. Adenosine is recommended for the acute treatment of SVT in pregnant women. The usual recommended doses may be used, although higher doses may be needed in some cases (Page [ACC/AHA/HRS 2015]). ACLS guidelines suggest use is safe and effective in pregnancy (ACLS [Neumar 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21096295\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if adenosine is excreted in breast milk following maternal administration. Adenosine is endogenous in breast milk (Sugawara 1995). Due to the potential for adverse reactions in the nursing infant, the manufacturer recommends a decision be made to interrupt nursing or not administer adenosine taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1620757\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid dietary caffeine for at least 12 hours prior to pharmacologic stress testing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130664\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, heart rate, blood pressure; consult individual institutional policies and procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130654\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antiarrhythmic actions:</b> Slows conduction time through the AV node, interrupting the re-entry pathways through the AV node, restoring normal sinus rhythm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myocardial perfusion scintigraphy:</b> Adenosine also causes coronary vasodilation and increases blood flow in normal coronary arteries with little to no increase in stenotic coronary arteries; thallium-201 uptake into the stenotic coronary arteries will be less than that of normal coronary arteries revealing areas of insufficient blood flow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130672\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Very brief </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Removed from systemic circulation primarily by vascular endothelial cells and erythrocytes (by cellular uptake); rapidly metabolized intracellularly; phosphorylated by adenosine kinase to adenosine monophosphate (AMP) which is then incorporated into high-energy pool; intracellular adenosine is also deaminated by adenosine deaminase to inosine; inosine can be metabolized to hypoxanthine, then xanthine and finally to uric acid. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: &lt;10 seconds</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322965\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adenocard Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/2 mL (2 mL): $43.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/4 mL (4 mL): $82.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adenoscan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/mL (20 mL): $261.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adenosine (Diagnostic) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/mL (20 mL): $128.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adenosine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/2 mL (2 mL): $13.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/4 mL (4 mL): $26.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Adenosine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/20 mL (20 mL): $50.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg/30 mL (30 mL): $76.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130676\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adcus (IE);</li>\n      <li>Adecard (VN);</li>\n      <li>Adenocard (BR);</li>\n      <li>Adenocor (AU, BE, BG, CY, CZ, DK, EE, EG, ES, FI, GB, GR, HU, IE, IL, JO, KR, LU, MT, MY, NL, NZ, PE, PL, PT, QA, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, ZA);</li>\n      <li>Adenoject (IN);</li>\n      <li>Adenoscan (AU, ES, HK, JP);</li>\n      <li>Adenosina Biol (AR);</li>\n      <li>Adenozer (TW);</li>\n      <li>Adesin (BD);</li>\n      <li>Adrekar (AT, DE);</li>\n      <li>Anosin (KR);</li>\n      <li>ATP-Long (UA);</li>\n      <li>Cardimax (PE);</li>\n      <li>Denosin (KR, VN);</li>\n      <li>Krenosin (FR, IT, LU, MX);</li>\n      <li>Krenosine (CH);</li>\n      <li>Odesin (BD);</li>\n      <li>Pisdeno (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Soladeno (LK);</li>\n      <li>Tricor (CL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adenocard (adenosinde) [product monograph]. Markham, Ontario, Canada: Astellas Pharma Canada; March 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adenoscan (adenosinde) [prescribing information]. Deerfield, IL: Astellas; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang M, Wrenn K. Adenosine dose should be less when administered through a central line. <i>J Emerg Med</i>. 2002;22(2):195-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/11858927 /pubmed\" target=\"_blank\" id=\"11858927 \">11858927 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delacr&eacute;taz E, &ldquo;Clinical Practice: Supraventricular Tachycardia,&rdquo; <i>N Engl J Med</i>, 2006, 354(10):1039-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/16525141/pubmed\" target=\"_blank\" id=\"16525141\">16525141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2193560\"></a>DiMarco JP1, Miles W, Akhtar M, Milstein S, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group [published correction appears in <i>Ann Intern Med.</i> 1990;113(12):996] <i>Ann Intern Med.</i> 1990;113(2):104-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/2193560/pubmed\" target=\"_blank\" id=\"2193560\">2193560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Domanovits H, Laske H, Stark G, et al. Adenosine for the management of patients with tachycardias&mdash;a new protocol. <i>Eur Heart J</i>. 1994;15(5):589-593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/8055996/pubmed\" target=\"_blank\" id=\"8055996\">8055996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ellenbogen KA, Thames MD, DiMarco JP, et al, &ldquo;Electrophysiological Effects of Adenosine in the Transplanted Human Heart. Evidence of Supersensitivity,&rdquo; <i>Circulation</i>, 1990, 81(3):821-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/2306833/pubmed\" target=\"_blank\" id=\"2306833\">2306833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7605518\"></a>Furlong R1, Gerhardt RT, Farber P, Schrank K, Willig R, Pittaluga J. Intravenous adenosine as first-line prehospital management of narrow-complex tachycardias by EMS personnel without direct physician control. <i>Am J Emerg Med</i>. 1995;13(4):383-388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/7605518/pubmed\" target=\"_blank\" id=\"7605518\">7605518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25 suppl):D60-D72. doi: 10.1016/j.jacc.2013.10.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/24355643/pubmed\" target=\"_blank\" id=\"24355643\">24355643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>Eur Heart J</i>. 2009;30(20):2493-2537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/19713419 /pubmed\" target=\"_blank\" id=\"19713419 \">19713419 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrison JK, Greenfield RA, and Wharton JM, &ldquo;Acute Termination of Supraventricular Tachycardia by Adenosine During Pregnancy,&rdquo; <i>Am Heart J</i>, 1992, 123(5):1386-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/1575160/pubmed\" target=\"_blank\" id=\"1575160\">1575160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al, &ldquo;Stress Protocols and Tracers,&rdquo; <i>J Nuc Cardiol</i>, 2006, 13(6):e80-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/17174798/pubmed\" target=\"_blank\" id=\"17174798\">17174798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19623049\"></a>Marill KA1, Wolfram S, Desouza IS, et al. Adenosine for wide-complex tachycardia: efficacy and safety. <i>Crit Care Med</i>. 2009;37(9):2512-2518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/19623049/pubmed\" target=\"_blank\" id=\"19623049\">19623049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntosh-Yellin NL, Drew BJ, and Scheinman MM, &ldquo;Safety and Efficacy of Central Intravenous Bolus Administration of Adenosine for Termination of Supraventricular Tachycardia,&rdquo; <i>J Am Coll Cardiol</i>, 1993, 22(3):741-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/8354807/pubmed\" target=\"_blank\" id=\"8354807\">8354807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo; <i>Circulation</i>, 2009, 119(16):2250-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/19332472/pubmed\" target=\"_blank\" id=\"19332472\">19332472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care [published corrections appear in <i>Circulation</i>. 2013;128(25):e480; <i>Circulation</i>. 2011;123(6):e236]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rich S, Kaufmann E, and Levy PS, &ldquo;The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,&rdquo; <i>N Engl J Med,</i> 1992, 327(2):76-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/1603139/pubmed\" target=\"_blank\" id=\"1603139\">1603139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25908694\"></a>R&ouml;ther J, Achenbach S, Tr&ouml;bs M, et al. Comparison of standard- and high-dose intracoronary adenosine for the measurement of coronary fractional flow reserve (FFR). <i>Clin Res Cardiol</i>. 2016;105(12):1003-1010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/25908694/pubmed\" target=\"_blank\" id=\"25908694\">25908694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25908694\"></a>Schlundt C, Bietau C, Klinghammer L, et al. Comparison of intracoronary versus intravenous administration of adenosine for measurement of coronary fractional flow reserve. <i>Circ Cardiovasc Interv</i>. 2015. 8(5).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/25908694/pubmed\" target=\"_blank\" id=\"25908694\">25908694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrader BJ, Inbar S, Kaufmann L, et al, &ldquo;Comparison of the Effects of Adenosine and Nifedipine in Pulmonary Hypertension,&rdquo; <i>J Am Coll Cardiol</i>, 1992, 19(5):1060-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/1552096/pubmed\" target=\"_blank\" id=\"1552096\">1552096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugawara M, Sato N, Nakano T, et al, &quot;Profile of Nucleotides and Nucleosides of Human Milk,&quot; <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1995, 41(4):409-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/8676214/pubmed\" target=\"_blank\" id=\"8676214\">8676214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuo XR, Zhang R, Jiang X, et al. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers. <i>Am J Cardiol</i>. 2012;109(12):1801-1806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/adenosine-drug-information/abstract-text/22459309 /pubmed\" target=\"_blank\" id=\"22459309 \">22459309 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9359 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130686\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130687\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F130728\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F130690\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F130709\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F130691\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671324\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671325\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130666\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F130651\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F130670\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F130669\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720645\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174500\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130658\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130673\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130655\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298689\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130660\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130662\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130675\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21096295\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F1620757\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F130664\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130654\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F130672\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322965\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130676\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9359|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=adenosine-patient-drug-information\" class=\"drug drug_patient\">Adenosine: Patient drug information</a></li><li><a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">Adenosine: Pediatric drug information</a></li></ul></div></div>","javascript":null}